Literature DB >> 22673369

High-purity enrichment of functional cardiovascular cells from human iPS cells.

Bo Lin1, Jong Kim, Yanxin Li, Haiying Pan, Xonia Carvajal-Vergara, Guy Salama, Tao Cheng, Yong Li, Cecilia W Lo, Lei Yang.   

Abstract

AIMS: A variety of human inherited heart diseases affect the normal functions of cardiomyocytes (CMs), endothelial cells (ECs), or smooth muscle cells (SMCs). To study human heart disease and generate cardiac cells for basic and translational research, an efficient strategy is needed for production of cardiac lineages from human stem cells. In the present study, a highly reproducible method was developed that can simultaneously enrich a large number of CMs and cardiac SMCs and ECs from human induced pluripotent stem (iPS) cells with high purity. METHODS AND
RESULTS: Human multipotent cardiovascular progenitor cells were generated from human iPS cells, followed by selective differentiation of the multipotent cardiovascular progenitor cells into CMs, ECs, and SMCs. With further fluorescence-activated cell sorting, each of the three cardiovascular cell types could be enriched with high purity (>90%). These enriched cardiovascular cells exhibited specific gene expression signatures and normal functions when assayed both in vitro and in vivo. Moreover, CMs purified from iPS cells derived from a patient with LEOPARD syndrome, a disease characterized by cardiac hypertrophy, showed the expected up-regulated expression of genes associated with cardiac hypertrophy.
CONCLUSIONS: Overall, our technical advance provides the means for generating a renewable resource of pure human cardiovascular cells that can be used to dissect the mechanisms of human inherited heart disease and for the future development of drug and cell therapeutics for heart disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22673369      PMCID: PMC4415083          DOI: 10.1093/cvr/cvs185

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  37 in total

Review 1.  Endothelial potential of human embryonic stem cells.

Authors:  Shulamit Levenberg; Janet Zoldan; Yaara Basevitch; Robert Langer
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113

2.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Authors:  Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

3.  Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines.

Authors:  Steven J Kattman; Alec D Witty; Mark Gagliardi; Nicole C Dubois; Maryam Niapour; Akitsu Hotta; James Ellis; Gordon Keller
Journal:  Cell Stem Cell       Date:  2011-02-04       Impact factor: 24.633

4.  SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells.

Authors:  Nicole C Dubois; April M Craft; Parveen Sharma; David A Elliott; Edouard G Stanley; Andrew G Elefanty; Anthony Gramolini; Gordon Keller
Journal:  Nat Biotechnol       Date:  2011-10-23       Impact factor: 54.908

5.  BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm.

Authors:  Valerie Gouon-Evans; Lise Boussemart; Paul Gadue; Dirk Nierhoff; Christoph I Koehler; Atsushi Kubo; David A Shafritz; Gordon Keller
Journal:  Nat Biotechnol       Date:  2006-11-05       Impact factor: 54.908

6.  Modelling the long QT syndrome with induced pluripotent stem cells.

Authors:  Ilanit Itzhaki; Leonid Maizels; Irit Huber; Limor Zwi-Dantsis; Oren Caspi; Aaron Winterstern; Oren Feldman; Amira Gepstein; Gil Arbel; Haim Hammerman; Monther Boulos; Lior Gepstein
Journal:  Nature       Date:  2011-01-16       Impact factor: 49.962

7.  Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome.

Authors:  Xonia Carvajal-Vergara; Ana Sevilla; Sunita L D'Souza; Yen-Sin Ang; Christoph Schaniel; Dung-Fang Lee; Lei Yang; Aaron D Kaplan; Eric D Adler; Roye Rozov; Yongchao Ge; Ninette Cohen; Lisa J Edelmann; Betty Chang; Avinash Waghray; Jie Su; Sherly Pardo; Klaske D Lichtenbelt; Marco Tartaglia; Bruce D Gelb; Ihor R Lemischka
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

8.  Isolation of cardiac cells from E8.5 yolk sac by ALCAM (CD166) expression.

Authors:  Yoshinobu Murakami; Hirokazu Hirata; Yoshiaki Miyamoto; Ayako Nagahashi; Yoshiki Sawa; Martin Jakt; Takayuki Asahara; Shin Kawamata
Journal:  Mech Dev       Date:  2007-09-20       Impact factor: 1.882

9.  Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.

Authors:  Elena Matsa; Divya Rajamohan; Emily Dick; Lorraine Young; Ian Mellor; Andrew Staniforth; Chris Denning
Journal:  Eur Heart J       Date:  2011-03-02       Impact factor: 29.983

10.  A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability.

Authors:  Paul W Burridge; Susan Thompson; Michal A Millrod; Seth Weinberg; Xuan Yuan; Ann Peters; Vasiliki Mahairaki; Vassilis E Koliatsos; Leslie Tung; Elias T Zambidis
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

View more
  41 in total

1.  Mechanism of automaticity in cardiomyocytes derived from human induced pluripotent stem cells.

Authors:  Jong J Kim; Lei Yang; Bo Lin; Xiaodong Zhu; Bin Sun; Aaron D Kaplan; Glenna C L Bett; Randall L Rasmusson; Barry London; Guy Salama
Journal:  J Mol Cell Cardiol       Date:  2015-01-30       Impact factor: 5.000

Review 2.  In vitro models of angiogenesis and vasculogenesis in fibrin gel.

Authors:  Kristen T Morin; Robert T Tranquillo
Journal:  Exp Cell Res       Date:  2013-06-22       Impact factor: 3.905

3.  Reprogramming approaches in cardiovascular regeneration.

Authors:  Sophie Dal-Pra; Maria Mirotsou
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-08

4.  Efficient generation of human embryonic stem cell-derived cardiac progenitors based on tissue-specific enhanced green fluorescence protein expression.

Authors:  Kornélia Szebényi; Adrienn Péntek; Zsuzsa Erdei; György Várady; Tamás I Orbán; Balázs Sarkadi; Ágota Apáti
Journal:  Tissue Eng Part C Methods       Date:  2015-01       Impact factor: 3.056

5.  HBL1 Is a Human Long Noncoding RNA that Modulates Cardiomyocyte Development from Pluripotent Stem Cells by Counteracting MIR1.

Authors:  Juli Liu; Yang Li; Bo Lin; Yi Sheng; Lei Yang
Journal:  Dev Cell       Date:  2017-08-21       Impact factor: 12.270

Review 6.  Human pluripotent stem cell-derived cardiac stromal cells and their applications in regenerative medicine.

Authors:  Martha E Floy; Taylor D Mateyka; Koji L Foreman; Sean P Palecek
Journal:  Stem Cell Res       Date:  2020-04-27       Impact factor: 2.020

7.  Two-step induction of trabecular meshwork cells from induced pluripotent stem cells for glaucoma.

Authors:  Ajay Kumar; Tianyu Cheng; Weitao Song; Brandon Cheuk; Enzhi Yang; Lei Yang; Yubing Xie; Yiqin Du
Journal:  Biochem Biophys Res Commun       Date:  2020-07-01       Impact factor: 3.575

8.  Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts.

Authors:  Ashish Parikh; Divyang Patel; Charles F McTiernan; Wenyu Xiang; Jamie Haney; Lei Yang; Bo Lin; Aaron D Kaplan; Glenna C L Bett; Randall L Rasmusson; Sanjeev G Shroff; David Schwartzman; Guy Salama
Journal:  Circ Res       Date:  2013-06-07       Impact factor: 17.367

Review 9.  Potential of cardiac stem/progenitor cells and induced pluripotent stem cells for cardiac repair in ischaemic heart disease.

Authors:  Wei Eric Wang; Xiongwen Chen; Steven R Houser; Chunyu Zeng
Journal:  Clin Sci (Lond)       Date:  2013-10       Impact factor: 6.124

10.  The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine.

Authors:  Ana M Martins; Gordana Vunjak-Novakovic; Rui L Reis
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.